F182112+CD38 Clinical Trials

1 actively recruiting trial

Also known as: BCMA CD3, CD38 monoclonal antibody, F182112

Filter by location:

Other1 trial

A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.